Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-02-14
2009-08-25
Whiteman, Brian (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C436S524000
Reexamination Certificate
active
07579456
ABSTRACT:
The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 4683195 (1987-07-01), Mullis
patent: 4935363 (1990-06-01), Brown et al.
patent: 4959309 (1990-09-01), Dattagupta et al.
patent: 5070010 (1991-12-01), Hsu
patent: 5262564 (1993-11-01), Kun et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5338671 (1994-08-01), Scalice et al.
patent: 5459015 (1995-10-01), Janjic et al.
patent: 5475096 (1995-12-01), Gold et al.
patent: 5496938 (1996-03-01), Gold et al.
patent: 5503978 (1996-04-01), Schneider et al.
patent: 5567588 (1996-10-01), Gold et al.
patent: 5580737 (1996-12-01), Polisky et al.
patent: 5635615 (1997-06-01), Allen et al.
patent: 5637459 (1997-06-01), Burke et al.
patent: 5648214 (1997-07-01), Nieuwlandt et al.
patent: 5654151 (1997-08-01), Allen et al.
patent: 5660985 (1997-08-01), Pieken et al.
patent: 5668264 (1997-09-01), Janjic et al.
patent: 5674685 (1997-10-01), Janjic et al.
patent: 5683867 (1997-11-01), Biesecker et al.
patent: 5705337 (1998-01-01), Gold et al.
patent: 5707796 (1998-01-01), Gold et al.
patent: 5723323 (1998-03-01), Kauffman et al.
patent: 5763173 (1998-06-01), Gold et al.
patent: 5789157 (1998-08-01), Jensen et al.
patent: 5861254 (1999-01-01), Schneider et al.
patent: 6011020 (2000-01-01), Gold et al.
patent: 6013443 (2000-01-01), Heilig et al.
patent: 6020130 (2000-02-01), Gold et al.
patent: 6051698 (2000-04-01), Janjic et al.
patent: 6229002 (2001-05-01), Janjic et al.
patent: 6395888 (2002-05-01), Biesecker et al.
patent: 6566343 (2003-05-01), Biesecker et al.
patent: 6573299 (2003-06-01), Petrus
patent: 2004/0249130 (2004-12-01), Stanton et al.
patent: 2005/0214308 (2005-09-01), Ashkenazi et al.
patent: 2006/0018871 (2006-01-01), Benedict et al.
patent: 0592035 (1996-01-01), None
patent: 2 183 661 (1987-06-01), None
patent: WO89/06694 (1989-07-01), None
patent: WO91/14436 (1991-10-01), None
patent: WO91/19813 (1991-12-01), None
patent: WO92/05285 (1992-04-01), None
patent: WO92/14842 (1992-09-01), None
patent: WO92/14843 (1992-09-01), None
patent: WO 98/18480 (1998-05-01), None
Watson et al. (Antisense & Nucleic Acid Drug Development 10:63-75, 2000).
Invitation to Pay Additional Fees for PCT/US06/05215, mailed Apr. 18, 2007.
Acosta et al., “Molecular basis for a link between complement and the vascular complications of diabetes”,PNAS(2002) 97(10): 5450-5455.
Agrawal et al., “Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies”,Proc. Natl. Acad. Sci. USA(1997) 94: 2620-2625.
Agrawal et al., “Novel enzymatic and immunological responses to oligonucleotides”,Tox. Lett. (1995) 82/83: 431-434.
Albrecht et al., “C5a-Induced Gene Expression in Human Umbilical Vein Endotheilial Cells”,Am. J. Pathology(2004) 164(3): 849-859.
Allegretti et al., “Targeting C5a: Recent Advances in Drug Discovery”,Curr. Med. Chem. (2005) 12: 217-236.
Altschul et al., “Basic Local Alignment Search Tool”,J. Mol. Biol. (1990) 215: 403-410.
Altschul et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”,Nuc. Acids Res.(1997) 25(17): 3389-3402.
Andrake, “DNA polymerase of bacteriophage T4 is an autogenous translational repressor”,Proc. Natl. Acad. Sci. USA(1988) 85: 7942-7946.
Baldwin et al., “Complement in Organ Transplantation: Contributions to Inflammation, Injury, and Rejection”,Transplantation(1995) 59(6): 797-808.
Baudouin et al, “Immunohistopathologic Findings in Proliferative Diabetic Retinopathy”,Am. J. Ophthalmol. (1988) 105: 383-388.
Bednar et al., “Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke”,J. Neurosurg. (1997) 86: 139-142.
Bhole, D. and Stahl, G.L., “Therapeutic potential of targeting the complement cascade in critical care medicine”,Crit. Care Med. (2003) 31(1 Suppl.): S97-S104.
Biesecker et al., “Derivation of RNA aptamer inhibitors of human complement C5”,Immunopharmacology(1999) 42: 219-230.
Biesecker, “Renal Localization of the Membrane Attack Complex in Systemic Lupus Erythematosus Nephritis”,J. Exp. Med. (1981) 154: 1779-1794.
Brauer et al., “The Contribution of Terminal Complement Components to Acute and Hyperacute Allograft Rejection in the Rat”,Transplantation(1995) 59(2): 288-293.
Brus et al., “Physiochemical and Biological Characterization of Polyethylenimine-graft-Poly(ethylene glycol) Block Copolymers as a Delivery System for Oligonucleotides and Ribozymes”,Bioconjugate Chem. (2004) 15: 677-684.
Carey et al., “Sequence-specific interaction of R17 coat protein with its ribonucleic acid binding site”,Biochem. (1983) 22: 2601-2610.
Chen et al., “Pharmacologic C5-Complement Suppression Reduces Blood Loss During On-Pump Cardiac Surgery”,J. Card. Surg. (2005) 20: 35-41.
Chen et al., “Selection of high-affinity RNA ligands to reverse transcriptase: Inhibition of cDNA synthesis and RNase H activity”,Biochem. (1994) 33: 8746-8756.
Cohen et al., “Interactions of hormonal steroids with nucleic acids: A specific requirement for guanine”,Proc. Natl. Acad. Sci. USA(1969) 63: 458-464.
Cotton et al., “2′-O-methyl, 2′O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event,”Nuc. Acids Res. (1991) 19(10): 2629-2635.
Davis et al., “Identifying consensus patterns and secondary structure in SELEX sequence sets”,Methods in Enzymology(1996) 267: 302-314.
Dehouck et al., “Blood-brain barrier in vitro—rapid evaluation of strategies for achieving drug targeting to the central nervous system”,Biol. Physiology of the Blood Brain Barrier, (1996) Couraud and Scherman eds., 23: 143-146.
Ellington and Szostak, “Abstracts of papers presented at the 1990 meeting on RNA Processing”, (1990) Cold Spring Harbor, NY, p. 84.
Evans et al., “In vitro and in vivo Inhibition of Complement Activity by a Single-Chain Fv Fragment Recognizing Human C5”,Mol. Immunol. (1995) 32(16): 1183-1195.
Fitch et al., “Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass”,Circulation(1999) 100: 2499-2506.
Fitzwater et al., “A SELEX primer”, (1996)Methods in Enzymology267: 275-301.
Froehler et al., “Synthesis of DNA via deoxynucleoside H-phosphonate intermediates,”Nuc. Acids Res. (1986) 14(13): 5399-5467.
Froehler, “Deoxynucleoside H-Phosphonate Diester Intermediates in the Synthesis of Internucleotide Phosphate Analogues”,Tet. Lett. (1986) 27(46): 5575-5578.
Gath et al., “The blood-CSF barrier in vitro”,Biol. and Physiology of the Blood Brain Barrier, (1996) Couraud and Scherman eds., 25: 153-158.
Gong et al., “Tubing Loops as a Model for Cardiopulmonary Bypass Circuits: Both the Biomaterial and the Blood-Gas Phase Interfaces Induce Complement Activation in an In Vitro Model”,J. Clin. Immunol. (1996) 16(4): 222-229.
Gerl et al., “Extensive Deposits of Complement C3d and C5b-9 in the Choriocapillaries of Eyes of Patients with Diabetic Retinopathy”,Invest. Opthalmol. Vis. Sci. (2002) 43(4): 1104-1108.
Granger et al., “Pexeluzimab, an Anti-C5 complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction”,Circulation(2003) 108: 1184-1190.
Green et al., “Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor”,Chemistry&Biology
Benedict Claude
Epstein David
Kurz Jeffrey
Kurz Markus
McCauley Dilara
Archemix Corp.
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Whiteman Brian
LandOfFree
Aptamer therapeutics useful in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aptamer therapeutics useful in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aptamer therapeutics useful in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4137122